Skip to main content
Caplight Logo









MitoSense, Inc.

MitoSense, Inc.

Private
Plymouth, MassachusettsHealthcare & Life Scienceshttps://www.mitosenseinc.com/

Last Round

Seed

Jan 26, 2024

Total Funding Raised

$3.5M

Company Overview

MitoSense, Inc. is a biotechnology company that develops treatments for neurodegenerative diseases using its proprietary Mitochondria Organelle Transplantation (MOT) technology to replenish mitochondria.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

mitochondria organelle transplantationMOTcellular biotherapyneurodegenerative disease treatmentmitochondrial therapyregenerative medicinebiotech R&DALS treatmentAlzheimer's researchParkinson's disease therapymitochondrial dysfunctionpreclinical developmentbiohackinglongevity science

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

MitoSense, Inc. Comparables

Compare MitoSense, Inc. with similar companies based on industry and business-model similarity.

MitoSense, Inc. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Mitrix Bio
84%
PAEAN Biotechnology
81%
LUCA Science
79%

MitoSense, Inc. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedJan 26, 2024
SeedFeb 8, 2023

MitoSense, Inc. Investors

Notable investors and investment history

MitoSense, Inc. investors
InvestorRounds
Caydan Capital PartnersSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 26, 2024

    Raised $2M in a Seed round.

Recent news

Latest coverage and updates

  • partners_withJul 23, 2026

    MitoSense, Inc. partnered with Aquilahealth on Jul 23rd '26.

  • partners_withJul 13, 2026

    MitoSense, Inc. partnered with Pitt on Jul 13th '26.

MitoSense, Inc. Filings

Explore SEC and related filing metadata, where available.

MitoSense, Inc. filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about MitoSense, Inc.'s valuation, stock price, and market status.

Is MitoSense, Inc. a public or private company?

MitoSense, Inc. is a private company.

What is the current stock price of MitoSense, Inc.?

MitoSense, Inc. is a private company with no public stock price. No recent secondary market data is available.

How much is MitoSense, Inc. worth (valuation)?

Valuation information for MitoSense, Inc. is not publicly available.

Can I buy MitoSense, Inc. stock?

MitoSense, Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was MitoSense, Inc.'s last funding round?

MitoSense, Inc.'s most recent funding round was Seed on January 26, 2024.

Who are the main investors in MitoSense, Inc.?

Key investors in MitoSense, Inc. include Caydan Capital Partners.

Will MitoSense, Inc. IPO soon?

No public IPO plans have been announced for MitoSense, Inc..

How can I track MitoSense, Inc. secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor MitoSense, Inc.'s secondary market activity and sign up for updates.

Firmographic Details

HeadquartersPlymouth, Massachusetts
Employee Range1
Year Founded2019
Last FundingJan 26, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?